HEPTA Medical Secures €5.7 Million Series A, Led by BPI France to Advance Minimally Invasive Lung Cancer Treatment
- Founded in 2019 by Sofinnova’s medtech acceleration team, MD Start
- The funds will be used for the 510(k) regulatory approval process for the first version of HEPTA Medical’s microwave ablation platform and to initiate its clinical trials
SURESNES, France–(BUSINESS WIRE)–HEPTA Medical (“HEPTA”), a private medical device company dedicated to providing an efficient, safe, and minimally-invasive thermal ablation therapy for early-stage lung cancer, today announced it has successfully raised €5.7M in the first close of its Series A funding round. The investment was led by BPI France with the participation of M&L Healthcare and Clery IG.
This financing round will enable HEPTA to initiate the US regulatory approval process for the first version of its microwave ablation platform and to commence its clinical trials. Lung cancer is the leading cause of cancer-related deaths worldwide. As lung cancer screening programs are being implemented, the management of early-stage lung cancer patients has become an increasingly urgent concern for healthcare organizations. HEPTA aims to address this need by offering a controlled, incision-less technology, that provides a minimally invasive approach to treat patients quickly, safely, and efficiently.
